Molecular Templates has been granted a patent for PD-L1 binding molecules conjugated to a toxin, targeting PD-L1 positive tumor cells. The method involves administering the molecule to treat cancer in humans with PD-L1 expressing tumors. The molecules can selectively kill specific cells and deliver cargos for therapeutic and diagnostic purposes. GlobalData’s report on Molecular Templates gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Molecular Templates Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Molecular Templates, Peptide pharmacophores was a key innovation area identified from patents. Molecular Templates's grant share as of February 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Pd-l1 binding molecule for treating cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Molecular Templates Inc

A recently granted patent (Publication Number: US11918649B2) discloses a method for treating cancer in human subjects by administering a PD-L1 binding molecule containing a Shiga toxin effector polypeptide and a binding region that specifically targets the extracellular part of PD-L1. The binding region includes specific amino acid sequences in the heavy chain variable region (VH) and light chain variable region (VL) to ensure effective binding to PD-L1 expressing tumor cells. The method aims to provide a therapeutic benefit in various types of cancers characterized by PD-L1 expression, including solid tumors like bladder cancer, breast cancer, colon cancer, and others.

Furthermore, the patent claims detail specific sequences for the Shiga toxin effector polypeptide, VH, VL, and other components of the PD-L1 binding molecule to enhance its efficacy in targeting cancer cells. The method also addresses cancers with high mutational burden and those resistant to existing treatments like immunotherapies such as ipilimumab, nivolumab, and pembrolizumab. Additionally, the patent covers a range of cancer types, including glioma, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, and more, indicating the broad applicability of the proposed treatment approach. The method also accounts for metastatic cancers, providing a comprehensive strategy for addressing advanced stages of the disease.

To know more about GlobalData’s detailed insights on Molecular Templates, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies